Citikolin
S&D Pharma

Klinické štúdie s perorálnym roztokom (Cognizin®) u pacientov s glaukómom:

  • Rossetti L et al. The effect of citicoline oral solution on quality of life in patients with glaucoma: the results of an international, multicenter,randomized, placebo controlled cross over trial. Graefes Arch Clin Exp Ophthalmol.

    2023 Jun;261(6):1659-1668.

  • Arrico L et al. Oral citicoline: influence of long-term therapy on perimetric glaucoma defects. Panminerva Med.. 2023 Mar;65(1):96-99.*

  • Lanza M et al. Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up. Front Pharmacol. 2019 Sep 26;-10:1117.

  • Ottobelli L. et al. Citicoline oral solution in glaucoma: is there a role in slowing disease progression? Ophthalmologica. 2013;229(4):219-26.

* štúdie priamo s NEUROTitine® v dávke 10 ml denne (t. j. 500 mg denne perorálneho rotztoku citikolínu Cognizin®).

 

Klinické štúdie s očným roztokom citikolínu

  • u pacientov s glaukómom

Omk1

  • Rossetti L et al. Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial. J Glaucoma. 2020 Jul;29(7):513-520.

  • Carnevale C et al. Human vitreous concentrations of citicoline following topical application of citicoline 2% ophthalmic solution. PLoS 2014 May;62 (11): e0224982.

  • Parisi V et al. Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2015 Aug; 253(8):1327–40.

  • Roberti G et al. A preliminary study of the neuroprotective role of citicoline eye drops in glaucomatous optic neuropathy. Indian Journal of Ophthalmology 2014 May;62 (5)549-553.

Omk1-LF

  • Parisi V et al. Enhancement of Retinal Function and of Neural Conduction Along the Visual Pathway Induced by Treatment with Citicoline Eye Drops in Liposomal Formulation in Open Angle Glaucoma: A Pilot Electrofunctional Study. Adv Ther. 2019 Apr;36(4):987-996.

 

  • u pacientov so začínajúcou diabetickou retinopatiou

Omk2

  • Bandello F et al. Risultati della Survey Retinopatia Diabetica Incipiente REDI
    Studio osservazionale multicentrico in pazienti con Retinopatia Diabetica Incipiente, già in trattamento con Citicolina e Vitamina B12 in soluzione oftalmica NPT  Anno XXXIII 2023 n. 1/2023.

  • Parisi V et al. Citicoline and Vitamin B(12) Eye Drops in Type 1 Diabetes: Results of a 36-Month Pilot Study Evaluating Macular Electrophysiological Changes. Adv Ther. 2021 Jul;38(7):3924-3936.

  • Fogagnolo et al. Topical citicoline and vitamin B12 versus placebo in the treatment of corneal nerve damage: a randomized double-blind controlled trial.  BMC Ophthalmology 2020 Aug 1;20:315.

  • Parravano M et al. Citicoline and Eye Drops in Type 1 Diabetes: Results of a 3-year Pilot Study Evaluating Morpho-Functional Retinal Changes. Adv Ther. 2020 Apr;37(4):1646-1663.

 

 

Cognizin® je registrovaná značka spoločnosti KYOWA HAKKO BIO, Japonsko.
Prípravky Omk1, Omk1-LF a Omk2 obsahujú citikolín od spoločnosti KYOWA HAKKO BIO, Japonsko.

Neurotidine® je potravina na osobitné lekárske účely.

Omk1, Omk1-LF a Omk2 sú zdravotnícke pomôcky.